Despite decades of intense research on MeCP2, there is still no clear mechanism as to how MeCP2 dysfunction could lead to RTT; however, patient mutations tend to cluster in the methyl binding domain and transcriptional repressor domains of MeCP2, suggesting that transcriptional repression is inhibited in patients [97]. This evidence concerns the gene MECP2 and Rett syndrome.